CoChat
Cited by 229

The DOI matches its Crossref record.

Infliximab for Recurrent, Sight-Threatening Ocular Inflammation in Adamantiades–Behçet Disease

Sfikakis, P. P., Kaklamanis, P. H., Elezoglou, A., Katsilambros, N., Theodossiadis, P. G., Papaefthimiou, S., Markomichelakis, N. · 2004 · Annals of Internal Medicine

Abstract

Letters2 March 2004Infliximab for Recurrent, Sight-Threatening Ocular Inflammation in Adamantiades–Behçet DiseaseP. P. Sfikakis, MD, P. H. Kaklamanis, MD, A. Elezoglou, MD, N. Katsilambros, MD, P. G. Theodossiadis, MD, S. Papaefthimiou, MD, and N. Markomichelakis, MDP. P. Sfikakis, MDFrom Laikon Hospital, Athens University Medical School, 15452 Athens, Greece., P. H. Kaklamanis, MDFrom Laikon Hospital, Athens University Medical School, 15452 Athens, Greece., A. Elezoglou, MDFrom Laikon Hospital, Athens University Medical School, 15452 Athens, Greece., N. Katsilambros, MDFrom Laikon Hospital, Athens University Medical School, 15452 Athens, Greece., P. G. Theodossiadis, MDFrom Laikon Hospital, Athens University Medical School, 15452 Athens, Greece., S. Papaefthimiou, MDFrom Laikon Hospital, Athens University Medical School, 15452 Athens, Greece., and N. Markomichelakis, MDFrom Laikon Hospital, Athens University Medical School, 15452 Athens, Greece.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-140-5-200403020-00025 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Background: In Adamantiades–Behçet disease, recurrent ocular inflammation may lead to loss of vision despite continuous immunosuppressive therapy (1-3). Preliminary evidence suggests that the anti–tumor necrosis factor (TNF) monoclonal antibody infliximab rapidly controls sight-threatening inflammation, a critical factor in avoiding chronic, irreversible retinal lesions (4, 5).Objective: In this open, prospective study, we report on 25 patients who were treated with a single infliximab infusion at the immediate onset of a relapse. The primary outcome measure was the time to complete suppression of ocular inflammation. We also report on 15 of these patients who had experienced at least ...References1. Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behçet's disease. Semin Arthritis Rheum. 1998;27:197-217. [PMID: 9514126] CrossrefMedlineGoogle Scholar2. Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, et al . Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492-513. [PMID: 11024423] CrossrefMedlineGoogle Scholar3. Kaklamani VG, Kaklamanis PG. Treatment of Behçet's disease—an update. Semin Arthritis Rheum. 2001;30:299-312. [PMID: 11303303] CrossrefMedlineGoogle Scholar4. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behçet's disease [Letter]. Lancet. 2001;358:295-6. [PMID: 11498218] CrossrefMedlineGoogle Scholar5. Sfikakis PP. Behçet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis. 2002;61 Suppl 2 ii51-3. [PMID: 12379622] CrossrefMedlineGoogle Scholar6. Sfikakis PP, Kollias G. Tumor necrosis factor biology in experimental and clinical arthritis. Curr Opin Rheumatol. 2003;15:380-6. [PMID: 12819464] CrossrefMedlineGoogle Scholar7. Toker E, Kazokoglu H, Acar N. High dose intravenous steroid therapy for severe posterior segment uveitis in Behçet's disease. Br J Ophthalmol. 2002;86:521-3. [PMID: 11973245] CrossrefMedlineGoogle Scholar8. Alpsoy E, Durusoy C, Yilmaz E, Ozgurel Y, Ermis O, Yazar S, et al . Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol. 2002;138:467-71. [PMID: 11939808] CrossrefMedlineGoogle Scholar9. Gorman JD, Sack KE, Davis JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002;346:1349-56. [PMID: 11986408] CrossrefMedlineGoogle Scholar10. Ahmad T, Wallace GR, James T, Neville M, Bunce M, Mulcahy-Hawes K, et al . Mapping the HLA association in Behçet's disease: a role for tumor necrosis factor polymorphisms? Arthritis Rheum. 2003;48:807-13. [PMID: 12632436] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Laikon Hospital, Athens University Medical School, 15452 Athens, Greece. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByAdvances in the Treatment of Behcet's DiseaseTreatment of Neuro-Behçet's DiseaseAdamantiades–Behçet's DiseaseEffectiveness of Infliximab and Interferon Alpha-2a for the Treatment of Behçet's Uveitis: Customizing Therapy according to the Clinical FeaturesBehçet's disease uveitis: is there a need for new emerging drugs?Neuro-Behcet Disease and Ocular Inflammation: A Case Report and Literature ReviewThe current status of biological treatment for uveitisWeak association of a TNFRSF1A polymorphism with Behcet's disease in Chinese HanEffectiveness and Safety of Anti-Tumor Necrosis Factor-Alpha Agents Treatment in Behcets' Disease-Associated Uveitis: A Systematic Review and Meta-AnalysisDisease ManagementEye Disease in Behçet SyndromeAutoimmune and Autoanti

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-140-5-200403020-00025

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 229

Metadata

Authors
Sfikakis, P. P., Kaklamanis, P. H., Elezoglou, A., Katsilambros, N., Theodossiadis, P. G., Papaefthimiou, S., & Markomichelakis, N.
Venue
Annals of Internal Medicine
Published
2004-03-02
Volume
140
Issue
5
Pages
404-406
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2036131677
Cited by
229
References
0
FWCI
20.32
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Infliximab for Recurrent, Sight-Threatening Ocular Inflammation in Adamantiades–Behçet Disease. https://app.cochat.ai/papers/10.7326/0003-4819-140-5-200403020-00025
The paper
Sfikakis, P. P., Kaklamanis, P. H., Elezoglou, A., Katsilambros, N., Theodossiadis, P. G., Papaefthimiou, S., & Markomichelakis, N. (2004). Infliximab for Recurrent, Sight-Threatening Ocular Inflammation in Adamantiades–Behçet Disease. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-140-5-200403020-00025

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.